【6996 Financial Results】Derqi Pharmaceuticals Narrowed Loss to RMB 239 Million Last Year, No Final Dividend

SocialAnxietyStaker · 2026-03-21T00:34:36+00:00

Derqi Pharma's 2025 loss narrowed to 239 million yuan, primarily driven by cost control and efficiency improvements. Revenue reached 105 million yuan, up 14.5% year-over-year. Future focus will be on developing high-potential clinical assets and advancing products such as ATG-022 and ATG037.

SocialAnxietyStaker

2026-03-21 00:34:36

Abstract generation in progress

Deqi Medicine (06996)
Announces that for the full year ending last year, losses narrowed to RMB 239 million, compared to a loss of RMB 319 million in the same period last year. This was mainly due to strengthened cost control and increased efficiency, reducing R&D and administrative expenses; basic loss per share is RMB 0.38, with no final dividend declared.

Excluding net exchange differences, adjusted net loss for the period narrowed from RMB 304 million in 2024 to RMB 202 million in 2025, mainly due to the company’s enhanced cost control and efficiency improvements, reducing R&D and administrative costs. Revenue for the period was RMB 105 million, up 14.5% year-on-year, mainly driven by steady market penetration, deeper commercialization collaborations, and accelerated contributions from the Chinese market.

The report states that Deqi Medicine’s future focus is on accelerating the development of high-potential “first-in-class” and “best-in-class” clinical assets, laying the foundation for the next growth phase. The leading product is ATG-022 (CLDN18.2 ADC), which has shown efficacy in gastric cancer patients with different levels of CLDN18.2 expression; ATG037 (an oral CD73 inhibitor) also has the potential for accelerated approval in treating advanced melanoma resistant to CPI therapy.

Source: HKEX Announcement

Financial Hot Talk

Is the “Lobster Farming” craze over and the “Removal Trend” AI agent concept just a hype?

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes